Norepinephrine reuptake inhibitor
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
Norepinephrine reuptake inhibitors (NRIs), also known as noradrenaline reuptake inhibitors (NARIs), are compounds that elevate the extracellular level of the neurotransmitter norepinephrine in the central nervous system by inhibiting its reuptake from the synaptic cleft into the presynaptic neuronal terminal. The drugs inhibit the class of neurotransmitter transporters known as norepinephrine transporters. They have virtually no action at other monoamine transporters.
List of NRIs
- Atomoxetine (Strattera®)
- Reboxetine (Edronax®)
- Viloxazine (Vivalan®)
- Maprotiline (Ludiomil®)
- Bupropion (Wellbutrin®)
- Radafaxine (A drug related to Bupropion presently in clinical trials)
Strattera® is available in the United States and is indicated by the Food and Drug Administration (FDA) for the treatment of ADD and ADHD. Off-label uses include the treatment of depression and anxiety.
Reboxetine, unavailable in the United States and Canada, has been found to be effective at combating depression.
Radafaxine, a potent metabolite of Bupropion, is currently being developed by GlaxoSmithKline.
See also
de:Selektiver Noradrenalin-Wiederaufnahmehemmer
 | This medical treatment article is a stub. You can help WikiDoc by expanding it. |
